TSX:BLCO

Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results

Retrieved on: 
Mercoledì, Maggio 29, 2024
Medical Supplies, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Optical, PwC, Toronto Stock Exchange, Form 8-K, Bausch, Plan, TSX, Annual general meeting, Security (finance)

At the Annual Meeting, shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, approved an amendment and restatement of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the “Plan”) to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

Key Points: 
  • At the Annual Meeting, shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, approved an amendment and restatement of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the “Plan”) to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.
  • For the purposes of Toronto Stock Exchange (“TSX”) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.
  • The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com .

Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens

Retrieved on: 
Martedì, Maggio 28, 2024
Biotechnology, Pharmaceutical, Optical, Health, FDA, Medical Devices, Clinical Trials, Other Health, Presbyopia, Patient, Cataract, University, Envy, Astigmatism, Sale, Trial of the century, GLARE, DSM-IV codes, Contact, Dioptre, Bausch & Lomb, Health Canada, Freedom

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).
  • This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
  • “enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb.
  • Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the U.S. and Europe.

Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®

Retrieved on: 
Martedì, Maggio 28, 2024
Research, General Health, Pharmaceutical, Optical, Specialty, Retail, Clinical Trials, Science, Surgery, Medical Supplies, FDA, Health, The Bell Tower, Trial of the century, Viral, Bausch, Allergy, OD, Inflammation, Steroid, Fungal infection, Action, OnDemand, AOA, Telecanthus, CDT, Glaucoma, Sclera, Infection, Intraocular pressure, Contact, American Optometric Association, Conjunctiva, Cerebral edema, Music City Center, Macular edema, Complex, Eye injury, Thought, System, Employment, Convention, Contact lens, Slit lamp, Vaccinia, Patient, Incidence, Safety, Keratitis, Bausch & Lomb, Herpes simplex, Visual acuity, Taste, Iris, Eyelash, Risk, IOP, Lens (vertebrate anatomy), Astigmatism, Pigment, Efficacy, Verge, Ocular hypertension, Eye, Abstract, Human, Pain, Optic nerve, History, Palm, Chickenpox, EYE

The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.

Key Points: 
  • The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.
  • “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al.
  • “Improvement in Non-Invasive Tear Break-Up Time after Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et al.
  • During the event, attendees will have the opportunity to learn about Bausch + Lomb’s latest innovations, including Bausch + Lomb INFUSE® for Astigmatism and Blink NutriTears.

Bausch + Lomb Announces First-Quarter 2024 Results

Retrieved on: 
Mercoledì, Maggio 1, 2024
Surgery, Medical Devices, Health, Pharmaceutical, Optical, News, Bausch, Care, Bausch & Lomb, Mar, Forecasting, Tax, Acquisition, EPS, Adjustment, Advertising, Ophthalmology, GAAP, Growth, Pharmaceutical industry

Net loss attributable to Bausch + Lomb Corporation for the first quarter of 2024 was $167 million, as compared to $90 million for the first quarter of 2023, an unfavorable change of $77 million.

Key Points: 
  • Net loss attributable to Bausch + Lomb Corporation for the first quarter of 2024 was $167 million, as compared to $90 million for the first quarter of 2023, an unfavorable change of $77 million.
  • Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)1 for the first quarter of 2024 was $24 million, as compared to $34 million for the first quarter of 2023, a decrease of $10 million.
  • GAAP Earnings Per Share (“EPS”) Basic and Diluted attributable to Bausch + Lomb Corporation for the first quarter of 2024 was ($0.48), as compared to ($0.26) for the first quarter of 2023.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the first quarter of 2024 was $0.07, as compared to $0.10 for the first quarter of 2023.

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
Lunedì, Aprile 29, 2024
Vitamins, Supplements, Other Health, Retail, Other Science, Pharmaceutical, Research, Optical, Convenience Store, Medical Devices, Discount, Variety, Science, Clinical Trials, Medical Supplies, General Health, Surgery, Other Retail, Health, Specialty, Hydrogen, Verge, PAF, Frontiers Media, Efficacy, Safety, Trial of the century, Bausch & Lomb, MD, Erythritol, Development, Natural language, Convention (norm), Telecanthus, Research and development, Hosten, Toxicity, Comparison, Wood drying

The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.

Key Points: 
  • The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.
  • “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al.
  • “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al.
  • “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al.

Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Retrieved on: 
Giovedì, Aprile 25, 2024
Science, Other Science, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, Lutein, Safety, Bausch & Lomb, D3, Trial of the century, Development, Research and development, Curcumin, Anxiety, Frontiers, OSDI, Ageing

The clinical study met both primary endpoints:

Key Points: 
  • The clinical study met both primary endpoints:
    Change from baseline at day 56 in ocular symptoms measured by OSDI score.
  • The study also met secondary endpoints, showing statistically significant improvements in tear-film break-up time (TBUT), osmolarity, ocular surface health and presence of an inflammatory marker.
  • “More than 150 million people experience dry eyes in the U.S.,” said Yehia Hashad, M.D., executive vice president, Research & Development and chief medical officer, Bausch + Lomb.
  • “This could represent a significant opportunity for consumers looking for options when it comes to long-lasting dry eye symptom relief.”

Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs

Retrieved on: 
Giovedì, Aprile 18, 2024
Medical Supplies, Other Health, Health, Philanthropy, Pharmaceutical, Optical, Other Philanthropy, Recycling, Medical Devices, Surgery, Environment, Safety, Bausch, Microplastics, Sustainability, Bausch & Lomb, Partnership, Water, OD, Contact, Patient, Dependent and independent variables, Contact lens

Contact lenses, eye care and lens care materials are typically not processed in standard recycling facilities due to their small size and the type of plastic used to manufacture them.

Key Points: 
  • Contact lenses, eye care and lens care materials are typically not processed in standard recycling facilities due to their small size and the type of plastic used to manufacture them.
  • Eye health packaging materials collected through the Bausch + Lomb recycling programs are used to create various post-consumer products like picnic tables and benches.
  • The Biotrue Eye Care Recycling program, which launched in April 2021, has collected nearly 825,000 eye drop single dose units, lens cases, lens solution caps, as well as all Biotrue-branded eye drop bottles2.
  • In addition to the U.S., Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts .

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

Retrieved on: 
Lunedì, Aprile 15, 2024
General Health, Pharmaceutical, Discount, Variety, Optical, Supermarket, Specialty, Medical Devices, Convenience Store, Retail, Surgery, Biotechnology, Medical Supplies, Health, Bausch & Lomb, Bausch

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024.
  • Bausch + Lomb will host a conference call and live webcast at 8 a.m.
  • ET to discuss the results and provide a business update.
  • All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Mercoledì, Marzo 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

Retrieved on: 
Mercoledì, Febbraio 28, 2024
General Health, Health, Optical, Annual general meeting, Bausch & Lomb, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately.
  • Current director Richard De Schutter will retire from the Board effective as of the company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).
  • With Ms. Ling’s appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting.
  • “Since my return to the company, Richard has been a trusted advisor,” said Brent Saunders, chairman and CEO, Bausch + Lomb.